The EU Court of Justice ("CJEU") has recently clarified the scope of legal professional privilege ("LPP") under EU law. The CJEU ruled that LPP applies to all communications between EEA-qualified external lawyers and their...more
The long-awaited European Court of Justice's judgment in Towercast confirmed that national competition authorities (and national courts) can apply abuse of dominance rules to mergers that did not trigger EU and national...more
On 12 January 2023, the EU Court of Justice upheld the EU General Court’s judgment imposing a fine on Lithuanian Railways for dismantling a section of railway track. While reaffirming its essential facility case law...more
Advocate General Kokott has found that the General Court erred in law in requiring the European Commission to show anti-competitive effects of a merger with “strong probability” and that the scope of its judicial review was...more
10/28/2022
/ Anti-Competitive ,
Competition ,
EU ,
European Commission ,
European Court of Justice (ECJ) ,
Investment ,
Judicial Review ,
Mergers ,
Standard of Proof ,
Telecommunications ,
UK
Advocate General Juliane Kokott has proposed that the EU Court of Justice should find that competition authorities have the power to apply Article 102 TFEU to corporate transactions that are not reportable, and test under...more
On 18 May and 22 June 2022, the EU General Court upheld two European Commission prohibition decisions. Both judgments endorsed the European Commission's assessment of the mergers at issue, recognising a broad margin of...more
9/19/2022
/ Appeals ,
Buyers ,
Competition ,
Declaratory Judgments ,
EU ,
European Commission ,
European Court of Justice (ECJ) ,
European Merger Control Regulation ,
Merger Controls ,
Mergers ,
Remedies ,
Standard of Proof ,
Standard of Review
On 25 March 2021, the European Court of Justice ("ECJ") dismissed all the appeals against the European Commission's decision to fine Lundbeck and several other companies for entering into anti-competitive patent settlement...more
The European Court of Justice's ruling in Paroxetine, handed down in record time just before Brexit, confirms the narrow interpretation of restrictions by object given in other recent cases. It also clarified certain issues...more
2/19/2020
/ Abuse of Dominance ,
Anti-Competitive ,
Appeals ,
EU ,
European Court of Justice (ECJ) ,
Generic Drugs ,
Patent Litigation ,
Patents ,
Pharmaceutical Patents ,
Prescription Drugs ,
Reverse Payment Settlement Agreements ,
Treaty on the Functioning of the European Union (TFEU) ,
UK Brexit ,
UK Competition and Markets Authority (CMA) ,
UK Competition Appeal Tribunal (CAT)